22nd Century Group Inc.
XXII22nd Century Group Inc. (XXII) is a biotechnology company focused on developing and commercializing cigarettes, tobacco, and cannabis products with reduced health risks. The company has patented plant science technologies to alter nicotine and THC levels in plants, aiming to create alternatives with lower addiction potential and harm. Their products are primarily marketed toward adult consumers seeking less harmful options.
Company News
22nd Century Group reported Q1 2026 net revenues of $4.1 million with a net loss of $3.3 million. The company announced plans to expand VLN® cigarette distribution to over 5,000 retail outlets by end of 2026, with products now available in over 2,000 stores across 20 states. The company maintains zero long-term debt and $9.5 million in cash, whi...
22nd Century Group announced Q4 2025 results showing net revenues of $3.5M (down from $4.0M in Q3) and a net loss of $2.8M. The company reported achieving a debt-free balance sheet with $7.1M in cash and a $9.5M insurance settlement from the 2022 facility fire. The company is executing a strategic shift toward higher-margin branded VLN® products...
22nd Century Group received a $9.5 million insurance settlement for business interruption claims, causing its stock to surge 39% in after-hours trading. The company is focusing on its VLN reduced-nicotine cigarette product line and preparing for its Q3 earnings report.
22nd Century Group settled a business interruption insurance claim for $9.5 million, becoming debt-free and positioning itself to drive towards profitability in 2026 by focusing on its low-nicotine VLN® cigarette product.
22nd Century Group will host investor meetings on September 9, 2025, at the Lotte New York Palace Hotel during the HC Wainwright Conference, discussing their VLN® cigarette with 95% less nicotine.
